MedTech Strategist Issue: Vol. 6, No. 4 - March 13, 2019


Already a Subscriber?


Not a Subscriber?

Perspective - “The Future of Medical Device Innovation”

By David Cassak, Co-Editor-in-Chief

To create technologies for a value-based healthcare system, medtechs must shift their focus from outcome innovation to process innovation, and from structural fixes to modifying biology.



Heart Failure - “Will Heart Failure Be the Next Growth Market in Transcatheter Structural Heart?”

By Mary Stuart, Senior Writer/Market Analyst

As the clinical world redefines chronic heart failure populations, new targets for device intervention are emerging and at least four companies are developing novel transcatheter treatments for a type of heart failure that has been increasing in prevalence: heart failure with preserved ejection fraction. Now the most common type of failure, HFpEF offers an emerging device opportunity at the intersection of two high growth medical device markets: heart failure and structural heart.

Venture Capital - “As Some VCs Exit Medtech, Others Spot Opportunity”

By Melanie Senior, Contributing Writer

Many venture capitalists have fled medtech in search of higher, faster returns from biopharma. Now may be just the time for investors to return to attractively-valued medical device assets.



Regenerative Medicine - “Cornell’s Lawrence Bonassar’s Efforts to Scale 3D-Printed Biomaterials”

By Wendy Diller, Senior Writer/Market Analyst

Seemingly on the cusp of a regenerative medicine resurgence, leading US biomaterials scientist-entrepreneurs talk with MedTech Strategist about advances in both the regulatory framework and science of cell therapy-based approaches to treating intractable musculoskeletal conditions. The first of a three-part series focuses on Cornell University’s Lawrence Bonassar’s breakthroughs in materials processing, which aim to enable scaling up manufacturing of regenerative products.

Financing/M&A 2018 Wrap-up - “Good Year for IPOs and M&A Looks to Continue, Slowed Only by Government Shutdown”

By Stephen Levin, Co-Editor-in-Chief

The public market remained receptive to medtech companies and M&A remained active, although valuations dropped.  Looking ahead: IPO activity continues to appear promising if we can just keep the government open.



Neuromodulation - “Salvia BioElectronics: A Neurostimulation Platform for Migraine”

By Mary Stuart, Senior Writer/Market Analyst

The founders of Salvia BioElectronics aim to to give migraine sufferers back their lives. Building on research around known neural targets in migraine, the start-up is working to develop the right form factor for both effective stimulation and patient preference.

Hernia Repair - “TAS Medical: Putting Laparoscopic Hernia Repair in the Lead”

By Colin Miller, Contributing Writer

Ventral hernia repair is one of the most common surgical procedures. It is generally done via open surgery and almost always by placing a piece of surgical mesh along the abdominal muscle wall. The high cost and long recovery of open surgery coupled with the known complications of surgical mesh demonstrate a large unmet need. TAS Medical is introducing a trans-abdominal strap capable of achieving a more complete repair via a minimally invasive laparoscopic approach.


Not a Subscriber?

Already a Subscriber?

Want a Sample Article?

Companies Covered in this Issue: 3D Bio Corp., Abbott Laboratories Inc., Abiomed Inc., Alleviant Medical Inc., Alphabet Inc., Apple Inc., Inc., AstraZeneca PLC, Axonics Modulation Technologies Inc., Carbon Inc., CorAssist Cardiovascular Ltd., Corvia Medical Inc., Edwards Lifesciences Corp., ElectroCore LLC,  Endotronix Inc., Google Inc., Guardant Health Inc., Inspire Medical Systems Inc., Intuitive Surgical Inc., Johnson & Johnson, Johnson & Johnson Innovation LLC, Lightpoint Medical Ltd., LivaNova PLC, Medtronic PLC, Microsoft Corp., Miracor Medical Systems GMBH, Onkos Surgical, Organovo Holdings Inc., OrthoPediatrics Corp., Protembis GMBH, Ra Medical Systems Inc., Roche, Salvia BioElectronics BV, Shandong Weigao Group Medical Polymer Co., Shanghai RAAS Blood Products Co. Ltd., Shockwave Medical Inc., Siemens Healthineers AG, Stryker Corp., TAS Medical Twist Bioscience Corp., UnitedHealth Group, V-Wave Ltd., Verb Surgical Inc., Verily Life Sciences

Topics Covered in this Issue: Biopharma/Biomaterials; Business Strategies; Cardiovascular/Vascular; Digital Health; Cardiovascular/Vascular; Gastroenterology; Investors & Dealmaking; Neurology/Neurovascular; Perspective & Commentary; Start-Ups to Watch; Surgery/Robotics